WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018035951) NOVEL QUINOLINE COMPOUND
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/035951    International Application No.:    PCT/CN2016/102438
Publication Date: 01.03.2018 International Filing Date: 18.10.2016
IPC:
C07D 401/12 (2006.01), C07D 215/22 (2006.01), A61K 31/47 (2006.01), A61K 31/4709 (2006.01), A61K 31/506 (2006.01), A61P 35/00 (2006.01), A61P 35/02 (2006.01)
Applicants: HELIOEAST PHARMACEUTICAL CO., LTD. [CN/CN]; 789 Huoju Street, High-tech lndustrial Development Zone Nanchang, Jiangxi 330096 (CN)
Inventors: XU, Jun; (CN).
PENG, Hong; (CN).
ZHANG, Wenyan; (CN).
TAO, Lin; (CN).
ZHANG, Xiaoli; (CN).
ZHAO, Yan; (CN).
ZHAO, YinYing; (CN).
WANG, Xiaoxia; (CN).
LI, Yonghua; (CN).
ZOU, Yang; (CN)
Priority Data:
201610713451.9 24.08.2016 CN
Title (EN) NOVEL QUINOLINE COMPOUND
(FR) NOUVEAU COMPOSÉ DE QUINOLÉINE
(ZH) 一类喹啉类新化合物
Abstract: front page image
(EN)The present invention relates to a novel quinoline compound, wherein the compound is a compound of formula (I), a pharmaceutically acceptable salt, prodrug, metabolite, isotope derivative, or solvate thereof. The present invention further relates to a pharmaceutical composition comprising the compound, wherein the pharmaceutical composition can prevent or treat a disease or disorder related to a tyrosine kinase receptor. The present invention further relates to an application of the same as a tyrosine kinase inhibitor in medical, pharmaceutical, biological, physiological, and biochemical experiments.
(FR)La présente invention concerne un nouveau composé de quinoléine, le composé étant un composé de formule (I), un sel pharmaceutiquement acceptable, un promédicament, un métabolite, un dérivé d'isotope ou un solvate de celui-ci. La présente invention concerne en outre une composition pharmaceutique comprenant le composé, la composition pharmaceutique pouvant prévenir ou traiter une maladie ou un trouble lié à un récepteur de tyrosine kinase. La présente invention concerne en outre une application de celui-ci en tant qu'inhibiteur de tyrosine kinase dans des expériences médicales, pharmaceutiques, biologiques, physiologiques et biochimiques.
(ZH)本发明涉及一类喹啉类的新化合物,该化合物为式(I)化合物及其药学上可接受的盐、前药、代谢物、同位素衍生物和溶剂合物,及包含所述化合物的药物组合物,可用于预防或治疗与蛋白酪氨酸激酶受体相关的疾病和病症;及其可作为酪氨酸激酶抑制剂在医学、药学、生物学、生理学、生化学等实验中的应用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)